EMAIL THIS PAGE TO A FRIEND

Arteriosclerosis, thrombosis, and vascular biology

In vivo nanoparticle assessment of pathological endothelium predicts the development of inflow stenosis in murine arteriovenous fistula.


PMID 25395614

Abstract

In vivo assessment of pathological endothelium within arteriovenous fistula (AVF) could provide new insights into inflow stenosis, a common cause of AVF primary failure in end-stage renal disease patients. Here we developed nanoparticle-based imaging strategies to assess pathological endothelium in vivo and elucidate its relationship to neointimal hyperplasia formation in AVF. Jugular-carotid AVFs were created in C57BL/6 mice (n=38). Pathological endothelium in the AVF was visualized and quantified in vivo using dextranated magnetofluorescent nanoparticles (CLIO-VT680 [cross-linked iron oxide-VivoTag680]). At day 14, CLIO-VT680 was deposited in AVF, but only minimally in sham-operated arteries. Transmission electron microscopy revealed that CLIO-VT680 resided within endothelial cells and in the intimal extracellular space. Endothelial cells of AVF, but not control arteries, expressed vascular cell adhesion molecule-1 and showed augmented endothelial permeability near the anastomosis. Intravital microscopy demonstrated that CLIO-VT680 deposited most intensely near the AVF anastomosis (P<0.0001). The day 14 intravital microscopy CLIO-VT680 signal predicted the subsequent site and magnitude of AVF neointimal hyperplasia at day 42 (r=0.58, P<0.05). CLIO-VT680 deposition in AVF was further visualized by ex vivo MRI. AVF develop a pathological endothelial response that can be assessed in vivo via nanoparticle-enhanced imaging. AVF endothelium is activated and exhibits augmented permeability, offering a targeting mechanism for nanoparticle deposition and retention in pathological endothelium. The in vivo AVF nanoparticle signal identified and predicted subsequent inflow neointimal hyperplasia. This approach could be used to test therapeutic interventions aiming to restore endothelial health and to decrease early AVF failure caused by inflow stenosis.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

00268 Dextran, analytical standard, for GPC, 1,000
00269 Dextran, analytical standard, for GPC, 5,000
00270 Dextran, analytical standard, for GPC, 12,000
00271 Dextran, analytical standard, for GPC, 25,000
00891 Dextran, analytical standard, for GPC, 50,000
00892 Dextran, analytical standard, for GPC, 80,000
00893 Dextran, analytical standard, for GPC, 150,000
00894 Dextran, analytical standard, for GPC, 270,000
00895 Dextran, analytical standard, for GPC, 410,000
00896 Dextran, analytical standard, for GPC, 670,000
31394 Dextran, enzymatic synth.
31430 Dextran, analytical standard, for GPC, Set Mp 1,000-400,000
D0731000 Dextran, European Pharmacopoeia (EP) Reference Standard
D0731005 Dextran 1, European Pharmacopoeia (EP) Reference Standard
D0734000 Dextran 10 for calibration, European Pharmacopoeia (EP) Reference Standard
D0737000 Dextran 250 for calibration, European Pharmacopoeia (EP) Reference Standard
D0733000 Dextran 4 for calibration, European Pharmacopoeia (EP) Reference Standard
D0735000 Dextran 40 for calibration, European Pharmacopoeia (EP) Reference Standard
D0738000 Dextran 40 for performance test, European Pharmacopoeia (EP) Reference Standard
D0739000 Dextran 60/70 for performance test, European Pharmacopoeia (EP) Reference Standard
D0736000 Dextran 70 for calibration, European Pharmacopoeia (EP) Reference Standard
31416 Dextran from Leuconostoc mesenteroides, analytical standard, for GPC, Mw 1,000
31417 Dextran from Leuconostoc mesenteroides, analytical standard, for GPC, Mw 5,000
D9260 Dextran from Leuconostoc mesenteroides, average mol wt 9,000-11,000
31418 Dextran from Leuconostoc mesenteroides, analytical standard, for GPC, Mw 12,000
D4626 Dextran from Leuconostoc mesenteroides, average mol wt 15,000-30,000
31419 Dextran from Leuconostoc mesenteroides, analytical standard, for GPC, Mw 25,000
D1662 Dextran from Leuconostoc mesenteroides, average mol wt 35,000-45,000
31420 Dextran from Leuconostoc mesenteroides, analytical standard, for GPC, Mw 50,000
D3759 Dextran from Leuconostoc mesenteroides, average mol wt 48,000-90,000